Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about OMEROS CORPORATION
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
06/16OMEROS : Form 8-K)
PU
06/15OMEROS' : Narsoplimab pivotal trial data shared in oral presentation at 2021 ann..
AQ
06/14OMEROS : rsquo; Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 20..
BU
06/14Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentat..
CI
06/10OMEROS : Announces Publication Detailing the Mechanism of Action of PDE7 In Nico..
BU
06/09OMEROS : to Present at the BofA 2021 Napa BioPharma Virtual Conference
BU
06/09OMEROS : Says OMS906 Was Well-Tolerated in Phase 1 Trial in Alternative Pathway-..
MT
06/09OMEROS : Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
BU
06/09Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
CI
06/01SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
05/31OMEROS : Announces preliminary results from additional critically ill covid-19 p..
AQ
05/28OMEROS : Unveils Initial Results From Narsoplimab Treatment of Additional 'Criti..
MT
05/28OMEROS : Announces Preliminary Results from Additional Critically Ill COVID-19 P..
BU
05/28Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 ..
CI
05/20OMEROS' : Biologics License Application Review Period for Narsoplimab Extended b..
MT
05/20OMEROS : Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
BU
05/20Omeros Corporation Announces Extension of U.S. Food and Drug Administration R..
CI
05/14OMEROS' : Narsoplimab pivotal trial data to be shared as an oral presentation at..
AQ
05/13OMEROS : rsquo; Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentat..
BU
05/13Omeros Corporation Announces Data on Organ Function Improvement from Omeros’ ..
CI
05/12OMEROS : Reports First Quarter 2021 Financial Results (Form 8-K)
PU
05/10OMEROS : Q1 Earnings Snapshot
AQ
05/10Omeros Corporation Reports Earnings Results for the First Quarter Ended March..
CI
05/10OMEROS CORPORATION : Reports First Quarter 2021 Financial Results
BU
05/05OMEROS CORPORATION : to Announce First Quarter Financial Results on May 10, 2021
BU
05/04OMEROS CORPORATION : Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis a..
BU
05/04Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis ..
CI
04/26OMEROS : HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy R..
MT
03/23OMEROS : Quantum Leap Dose First Patients With Narsoplimab in COVID-19 Trial
MT
03/23OMEROS : and Quantum Leap Announce First Patients Dosed with Narsoplimab in the ..
BU
03/23Omeros and Quantum Leap Announces First Patients Dosed with Narsoplimab in th..
CI
03/01OMEROS : 4Q Earnings Snapshot
AQ
03/01OMEROS : Q4 Loss Widens As Revenue Tumbles
MT
03/01Omeros Corporation Reports Earnings Results for the Full Year Ended December ..
CI
03/01OMEROS CORPORATION : Reports Fourth Quarter and Year-End 2020 Financial Results
BU
02/25OMEROS CORPORATION : to Announce Fourth Quarter and Year-End Financial Results o..
BU
02/01OMEROS : UBS Starts Omeros at Buy With $25 Price Target
MT
01/26OMEROS : Hires Nadia Dac as Chief Commercial Officer
BU
01/26Omeros Corporation Appoints Nadia Dac as Its Chief Commercial Officer
CI
01/20OMEROS : HC Wainwright Adjusts Omeros' Price Target to $34 from $31, Keeps Buy R..
MT
01/20OMEROS : Wedbush Adjusts Omeros' Price Target to $18 From $13, Maintains Neutral..
MT
01/20OMEROS CORPORATION : - Biologics License Application for Narsoplimab in HSCT-TMA..
AQ
01/19OMEROS' : Biologics License Application for Blood Vessel Damage Treatment Candid..
MT
01/19OMEROS : Biologics License Application for Narsoplimab in HSCT-TMA Accepted for ..
BU
01/19Omeros Corporation Announces Biologics License Application for Narsoplimab in..
CI
01/11OMEROS : to Present at the 39th Annual J.P. Morgan Healthcare Conference
BU
2020OMEROS : Maxim Adjusts Omeros' Price Target to $25 from $20, Keeps Buy Rating
MT
2020OMEROS : CMS Confirms Continued Separate Payment for Omeros FDA-Approved OMIDRIA..
AQ
2020OMEROS : Gets Medicare Nod For Surgery Drug Omidira Pass-Through Billing Status ..
MT
2020OMEROS : CMS Confirms Continued Separate Payment for Omeros' FDA-Approved OMIDRI..
BU
2020Omeros Corporation Announces Centers for Medicare & Medicaid Services Confirm..
CI
2020OMEROS : Submits its Biologics License Application to U.S. FDA for Narsoplimab i..
AQ
2020OMEROS : Submits Biologics License Application to US FDA for Narsoplimab; Shares..
MT
2020OMEROS : Submits its Biologics License Application to U.S. FDA for Narsoplimab i..
BU
2020Omeros Corporation Submits its Biologics License Application to U.S. FDA for ..
CI
2020OMEROS : Wedbush Adjusts Omeros' Price Target to $13 From $12, Maintains Neutral..
MT
2020OMEROS : 3Q Earnings Snapshot
AQ
2020Omeros Corporation Reports Earnings Results for the Third Quarter Ended Septe..
CI
2020OMEROS : Earnings Flash (OMER) OMEROS CORPORATION Reports Q3 EPS $-0.34, vs. Str..
MT
2020OMEROS CORPORATION : Reports Third Quarter 2020 Financial Results
BU
2020OMEROS CORPORATION : to Announce Third Quarter Financial Results on November 9, ..
BU
2020OMEROS : Participates in Investor Conference Focused on COVID-19 Therapeutics in..
AQ
2020OMEROS : Participates in Investor Conference Focused on COVID-19 Therapeutics in..
BU
2020OMEROS : Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Tri..
AQ
2020OMEROS : Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Tri..
BU
2020Omeros Corporation Reports Final Efficacy and Safety Data from the Narsoplima..
CI
2020OMEROS : OMS906 Data Presented at Complement-based Drug Development Summit
AQ
2020OMEROS : Schedules Webcast to Present Final Efficacy Results from Narsoplimab BL..
AQ
2020OMEROS : rsquo; OMS906 Data Presented at Complement-based Drug Development Summi..
BU
2020OMEROS : Schedules Webcast to Present Final Efficacy Results from Narsoplimab BL..
BU
2020Omeros Corporation to Present Final Efficacy Results from Narsoplimab BLA for..
CI
2020Certain Common Stock of Omeros Corporation are subject to a Lock-Up Agreement..
CI
2020Certain Stock Options of Omeros Corporation are subject to a Lock-Up Agreemen..
CI
2020Certain Warrants of Omeros Corporation are subject to a Lock-Up Agreement End..
CI
1  2  3  4  5  6  7  8Next
Upcoming event on OMEROS CORPORATION
08/10/21